Data from Boston Scientific‘s (NYSE:BSX) Ranger SFA trial showed that treatment with its drug-coated balloon succeeded in the femoropopliteal segment after one year and resulted in greater rates of patency, with fewer interventions, compared to standard balloon angioplasty.
The results, which were published this month in JACC: Cardiovascular Interventions, demonstrated that both groups of patients – those treated with Boston Scientific’s Ranger DCB and those treated with standard balloon angioplasty – experienced similar quality-of-life improvements over the course of 12 months.
Get the full story at our sister site, Drug Delivery Business News.
The post Boston Scientific’s drug-coated balloon succeeds in femoropopliteal segment at one year appeared first on MassDevice.
from MassDevice https://ift.tt/2rFmxWK
Cap comentari:
Publica un comentari a l'entrada